Author(s):
Karishma P. Fuse, Vinod H. Jadhav
Email(s):
vj47422@gmail.com
DOI:
10.52711/2231-5675.2023.00005 
Address:
Karishma P. Fuse1, Vinod H. Jadhav2
1Department of Pharmaceutical Quality Assurance, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra, India.
2Quest Medpharma Consultants, Nagpur, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 1,
Year - 2023
ABSTRACT:
Nitrosamine impurities in pharmaceutical products have increased attention for safety in the direction of the use of various drugs. Nitrosamines are the class of compounds which represents nitroso group attached to an amine (R1N(-R2)-N=0). Nitrosamines are molecules that have a nitroso group connected to an amine (R1N(-R2)-N=0). Controlling cancer-causing contaminants in pharmaceutical products is critical for predicting and avoiding the carcinogenic risk of medicine in people. According to recent findings, nitrosamine impurities have increased the medicinal product's carcinogenic risk. The literature search was accomplished using PubMed, Google scholar, and the Cochrane library to identify relevant scientific articles using various sensitive techniques and analytical instruments for the detection of nitrosamine impurities from the years 1981 to 2022. The search terms included nitrosamine detection techniques, formation of nitrosamine, HPLC technique for nitrosamine detection, GC-MS/MS, GC-MS/MS, GC-MS-Head space, and GC-QTOF technique for nitrosamine detection, LC-MS/MS technique for nitrosamine detection, The literature search included 29 scientific articles from the English lamnguage, including original research and standard guidelines intended to review all the sensitive techniques for detection of nitrosamine impurities in pharmaceutical products. The current review aims to discuss the highly sensitive, cost effective, accurate and precise methods for the detection of various nitrosamine contaminations in the pharmaceutical products.
Cite this article:
Karishma P. Fuse, Vinod H. Jadhav. Insight into Analytical Techniques for the Detection of Nitrosamine Impurities: A Review. Asian Journal of Pharmaceutical Analysis. 2023; 13(1):30-4. doi: 10.52711/2231-5675.2023.00005
Cite(Electronic):
Karishma P. Fuse, Vinod H. Jadhav. Insight into Analytical Techniques for the Detection of Nitrosamine Impurities: A Review. Asian Journal of Pharmaceutical Analysis. 2023; 13(1):30-4. doi: 10.52711/2231-5675.2023.00005 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-1-5
REFERENCES:
1. Tuesuwan B, Vongsutilers V. Nitrosamine contamination in pharmaceuticals: Threat, impact, and control. Journal of Pharmaceutical Sciences. 2021 Sep 1;110(9):3118-28.https://doi.org/10.1016/j.xphs.2021.04.021
2. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry, Introduction, Available at https://www.fda.gov/media/141720/download#:~:text=FDA%20has%20identified%20seven%20nitrosamine,(NDBA)%2C%20and%20N%2DC
3. Vyas AJ, Godhaniya JP, et al. A review on carcinogenic impurities found in marketed drugs and strategies for its determination by analytical methods. Asian Journal of Pharmaceutical Analysis. 2021 May 13;11(2):159-69.
4. Zheng J, Kirkpatrick CL, et al. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products. The AAPS Journal. 2022 Feb;24(1):1-8. DOI: 10.1208/s12248-021-00669-8
5. Structure of Nitrosamine Drug Impurities and Implications for Chemical Analysis Available at https://acanthusresearch.com/aboutproducts/nitrosamine-impurities-analysis/ accessed date 30th Mar 2022.
6. Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004, Nitrosamine impurities in human medicinal products, Presence and formation of N-nitrosamines in human medicinal products, Available at https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf
7. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry, General Root Causes for the Presence of Nitrosamine Impurities in APIs. Available at https://www.fda.gov/media/141720/download#:~:text=FDA%20has%20identified%20seven%20nitrosamine,(NDBA)%2C%20and%20N%2D
8. Shaik KM, Sarmah B, et al. Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques. Critical reviews in analytical chemistry. 2022 Jan 2;52(1):53-71. DOI: 10.1080/10408347.2020.1788375
9. Li, W, Chen, N, et al. Online Coupling of Tandem Liquid-Phase Extraction with HPLC-UV for the Determination of Trace: N -Nitrosamines in Food Products. Anal. Methods 2018, 10, 1733–1739. https://doi.org/10.1039/C8AY00014J
10. Ho J, Wisneski H, et al. High Pressure Liquid Chromatographic-Thermal Energy Determination of N-Nitrosodiethanolamine in Cosmetics, Journal of Association of Official Analytical Chemists, Volume 64, Issue 4, 1 July 1981, Pages 800–804, https://doi.org/10.1093/jaoac/64.4.800
11. Masada S, Tsuji G, et al. Rapid and efficient high-performance liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products. Scientific Reports. 2019 Aug 14;9(1):1-6. DOI: 10.1038/s41598-019-48344-5
12. Shaik KM, Sarmah B, et al. Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques. Critical reviews in analytical chemistry. 2022 Jan 2;52(1):53-71. DOI: 10.1080/10408347.2020.1788375
13. U.S. Food & Drug Administration. 2019. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of NDMA in ranitidine drug substance and drug product. Test method. Available at: https://www. fda.gov/media/130801/download.
14. Chang SH, Chang CC, et al. A multi-analyte LC-MS/MS method for screening and quantification of nitrosamines in sartans. Journal of Food & Drug Analysis. 2020 Apr 1;28(2).https://doi.org/10.5478/MSL.2021.12.2.31
15. Soergel F,Kinzig M, et al. The contamination of valsartan and other Sartans, part 1: new findings. J Pharm Biomed Anal. 2019;172:395–405. DOI: 10.1016/j.jpba.2019.05.022
16. Baksam VK, Saritha N, et al . A Critical N-Nitrosamine Impurity of Anticoagulant Drug, Rivaroxaban: Synthesis, Characterization, Development of LC–MS/MS Method for Nanogram Level Quantification. Chromatographia. 2022 Jan 13:1-0.https://doi.org/10.1007/s10337-021-04115-x
17. Wohlfart J, Scherf-Clavel O, et al. The nitrosamine contamination of drugs, part 3: Quantification of 4-Methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS. Journal of Pharmaceutical and Biomedical Analysis. 2021 Sep 5;203:114205. DOI: 10.1016/j.jpba.2021.114205
18. Chidella KS, Dasari VB, et al. Ultra-Sensitive LC-MS/MS Method for the Trace Level Quantification of Six Potential Genotoxic Nitrosamine Impurities in Telmisartan. American Journal of Analytical Chemistry. 2021 Jun 10;12(6):227-40. DOI: 10.4236/ajac.2021.126014
19. Wu Q, Kvitko E, et al. A Broadly Accessible Liquid Chromatography Method for Quantification of Six Nitrosamine Compounds and N, N-Dimethylformamide in Metformin Drug Products Using High Resolution Mass Spectrometry. 10.26434/chemrxiv.13202849.v1
20. Shaik KM, Sarmah B, et al. Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques. Critical reviews in analytical chemistry. 2022 Jan 2;52(1):53-71. DOI: 10.1080/10408347.2020.1788375
21. Zheng J, Kirkpatrick CL, et al. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products. The AAPS Journal. 2022 Feb;24(1):1-8. DOI: 10.1208/s12248-021-00669-8
22. Wichitnithad W, Sudtanon O, et al. Development of a Sensitive Headspace Gas Chromatography–Mass Spectrometry Method for the Simultaneous Determination of Nitrosamines in Losartan Active Pharmaceutical Ingredients. ACS omega. 2021 Apr 16;6(16):11048-58. DOI: 10.1021/acsomega.1c00982
23. Giménez-Campillo C, Pastor-Belda M, et al. Development of a new methodology for the determination of N-nitrosamines impurities in ranitidine pharmaceuticals using microextraction and gas chromatography-mass spectrometry. Talanta. 2021 Feb 1;223:121659.https://doi.org/10.1016/j.talanta.2020.121659
24. Liu J, Xie B, et al. Development of a sensitive and stable GC-MS/MS method for simultaneous determination of four N-nitrosamine genotoxic impurities in sartan substances. Journal of Analytical Science and Technology. 2021 Dec;12(1):1-8. DOI
https://doi.org/10.1186/s40543-020-00254-2
25. B.A. Dawson, R.C. Lawrence, Analysis of selected drug formulations for volatile nitrosamines, Journal - Association of Official Analytical Chemists, 70 (1987) 554-556. https://doi.org/10.1093/jaoac/70.3.554
26. Lim HH, Oh YS, et al. Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography–tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2020 Sep 10;189:113460. DOI: 10.1016/j.jpba.2020.113460
27. Chang SH, Ho HY, et al. Screening of Nitrosamine Impurities in Sartan Pharmaceuticals by GC-MS/MS. Mass Spectrometry Letters. 2021;12(2):31-40.https://doi.org/10.5478/MSL.2021.12.2.31
28. Alshehri YM, Alghamdi TS, et al. HS-SPME-GC-MS as an alternative method for NDMA analysis in ranitidine products. Journal of pharmaceutical and biomedical analysis. 2020 Nov 30;191:113582. DOI: 10.1016/j.jpba.2020.113582
29. Schmidtsdorff S, Schmidt AH. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography. Journal of pharmaceutical and biomedical analysis. 2019 Sep 10;174:151-60. DOI: 10.1016/j.jpba.2019.04.049